CAR-T used in treatment of two men with mCRPC at UPenn

On a CureTalks conversation earlier today with Dr. Carl June of the University of Pennsylvania (UPenn), we learned that his team had very recently treated two men with metastatic, castration-resistant prostate cancer (mCRPC) using chimeric antibody receptor T-cell therapy (CAR-T). … READ MORE …

CAR-T in the treatment of cancer: a CureTalks telecon

On November 15, our friends at CureTalks will hold a telecon on which there will be a discussion about the current and potential future uses of CAR-T in the treatment of cancer with Prof. Carl June of the University of Pennsylvania. … READ MORE …

New test for abiraterone- and enzalutamide-resistant forms of prostate cancer

A group at The Institute for Cancer Research and The Royal Marsden Hospital in the UK — along with other European colleagues — has come up with a new, relatively low-cost test that seems to be able to identify men with advanced forms of prostate cancer who are more or less likely to respond well to treatment with drugs like abirateone acetate and enzalutamide. … READ MORE …

Data from the first really large trial of CAR-T in treatment of lymphoma

As yet, there has been no serious clinical exploration of whether the new types of CAR-T treatment can be applied to patients with either prostate cancer or any other form of solid tumor. … READ MORE …

ROR-γ: a new way to suppress androgen receptor expression?

Most of our readers will be familiar with the idea that progression of prostate cancer over time is associated with the expression of  androgen receptors (ARs) in prostate cancer tissue. … READ MORE …

Can the ex-Aragon team pull off a repeat with another new drug for mCRPC

According to an article by Alex Lash on the Xconomy web site, a start-up biotech company in South San Francisco called ORIC Pharmaceuticals will — at least initially — be highly focused on new drug therapies for men with very late-stage prostate cancer. … READ MORE …

The role of liquid biopsies in management of advanced prostate cancer

A newly published paper in Science Translational Medicine has added to our understanding of the future potential of liquid biopsies (e.g., blood, plasma, and similar samples) in the management of progressive forms of prostate cancer. … READ MORE …